Cardinal Bases Fee-For-Service Deals On Customer Profitability Analysis
Executive Summary
Cardinal's fee-for-service negotiations with drug manufacturers rely on the wholesaler's analysis of each company's profitability, Exec VP-Pharmaceutical Distribution Mark Parrish said
You may also be interested in...
Cardinal Fee-For-Service Distribution Transition Slows Earnings Growth
Cardinal's slower-than-expected conversion of its contracts to the fee-for-service distribution model has contributed to a slowdown in earnings growth
Cardinal Fee-For-Service Distribution Transition Slows Earnings Growth
Cardinal's slower-than-expected conversion of its contracts to the fee-for-service distribution model has contributed to a slowdown in earnings growth
McKesson Begins Fee-For-Service Deals With Small Manufacturers June 1
McKesson's core distribution agreements with small manufacturers will set the stage for discussions with its large pharma partners, CEO John Hammergren said